Cabaletta Bio (CABA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company overview and clinical progress

• Developing targeted curative cell therapies for autoimmune diseases since 2017, focusing on a CD19 CAR T product with a 4-1BB co-stim domain and 40 U.S. clinical sites enrolling patients for 11 indications, including lupus and myositis.

• Rapid movement toward registrational trials is anticipated after completion of initial Phase I and II studies, with a focus on drug-free clinical responses and organ failure prevention.

• Data from lupus, lupus nephritis, myositis, and scleroderma cohorts will be presented at the upcoming ACR conference, highlighting patient and physician enthusiasm.

• Clinical trial design allows for protocol modifications to accelerate transition from Phase II to Phase III without delays, leveraging site-specific expertise.

• Enrollment pace is accelerating, with the potential to reach Phase III ahead of competitors, supported by robust site engagement.

Product differentiation and innovation

• CABA-201 is a fully human 4-1BB CAR T product designed to replicate a successful murine binder, with dosing informed by preclinical and early clinical data.

• The company is pioneering a whole blood manufacturing process to eliminate the need for apheresis, aiming to simplify patient experience and broaden access.

• Trials are underway to test CABA-201 without preconditioning, which could significantly improve the treatment regimen if successful.

• Focus remains on achieving reliable, durable, drug-free clinical responses, with all immunosuppressants ideally eliminated in most patients.

• The approach is positioned as more durable and reliable than bispecifics or other modalities, with the goal of setting a new standard for autoimmune therapy.

Safety, data, and future outlook

• A grade four ICANS event occurred in one patient, considered an outlier due to unique cytokine profiles; detailed analysis will be presented at ACR.

• Ongoing safety monitoring and data transparency are emphasized, with the belief that accumulating data will clarify the product's safety profile.

• Seven to eight patients' data with up to six months of follow-up are expected to be presented at ACR.

• Durability of response is being assessed through sequential B cell receptor sequencing, aiming to rigorously define immune system reset and minimize recurrence risk.

• Increased site and patient enrollment post-protocol amendment, with momentum building toward registrational trials in 2025.